You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 1
  • CT-07 A phase 2, randomised, placebo-controlled, double-blind, ascending dose study to evaluate efficacy, safety, and tolerability, pharmacokinetics, pharmacodynamics and pharmacogenetics of CC-220 in subjects with systemic lupus erythematosus

Article info

Article menu

Download PDFPDF

Clinical Trials
CT-07 A phase 2, randomised, placebo-controlled, double-blind, ascending dose study to evaluate efficacy, safety, and tolerability, pharmacokinetics, pharmacodynamics and pharmacogenetics of CC-220 in subjects with systemic lupus erythematosus
Free

Authors

Citation

Werth V, Hough D, Korish S, et al
CT-07 A phase 2, randomised, placebo-controlled, double-blind, ascending dose study to evaluate efficacy, safety, and tolerability, pharmacokinetics, pharmacodynamics and pharmacogenetics of CC-220 in subjects with systemic lupus erythematosus
Lupus Science & Medicine 2016;3:doi: 10.1136/lupus-2016-000179.79

Publication history

  • First published August 31, 2016.
Online issue publication 
September 01, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions